Biotechnology company Phio Pharmaceuticals Corp (Nasdaq:PHIO) said on Friday that its board of directors has named Gerrit Dispersyn Dr Med. Sc., as its new chief executive officer.
Effective 1 March 2019, Dr Dispersyn will succeed the company's outgoing chief executive officer Geert Cauwenbergh, Dr. Med. Sc., who will be available to support the transition and will remain as a member of the board of directors.
Currently, Dr Dispersyn serves as the board member, president and chief operating officer of the company that was spun-off from its parent company in April 2012.
Most recently, Dr Dispersyn was employed as the chief development officer of the company, a position he has held since April 2017.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer